402 related articles for article (PubMed ID: 27354708)
1. Safety Evaluation of CNS Administered Biologics-Study Design, Data Interpretation, and Translation to the Clinic.
Vuillemenot BR; Korte S; Wright TL; Adams EL; Boyd RB; Butt MT
Toxicol Sci; 2016 Jul; 152(1):3-9. PubMed ID: 27354708
[TBL] [Abstract][Full Text] [Related]
2. Current advances in delivery of biotherapeutics across the blood-brain barrier.
Rajadhyaksha M; Boyden T; Liras J; El-Kattan A; Brodfuehrer J
Curr Drug Discov Technol; 2011 Jun; 8(2):87-101. PubMed ID: 21513485
[TBL] [Abstract][Full Text] [Related]
3. Differential receptor-mediated drug targeting to the diseased brain.
Rip J; Schenk GJ; de Boer AG
Expert Opin Drug Deliv; 2009 Mar; 6(3):227-37. PubMed ID: 19327042
[TBL] [Abstract][Full Text] [Related]
4. Nanotechnological advances for the delivery of CNS therapeutics.
Wong HL; Wu XY; Bendayan R
Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
[TBL] [Abstract][Full Text] [Related]
5. Nanotechnology-based drug delivery for central nervous system disorders.
Nguyen TT; Dung Nguyen TT; Vo TK; Tran NM; Nguyen MK; Van Vo T; Van Vo G
Biomed Pharmacother; 2021 Nov; 143():112117. PubMed ID: 34479020
[TBL] [Abstract][Full Text] [Related]
6. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
Begley DJ
Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
[TBL] [Abstract][Full Text] [Related]
7. Intranasal drug delivery to the central nervous system: present status and future outlook.
Tayebati SK; Nwankwo IE; Amenta F
Curr Pharm Des; 2013; 19(3):510-26. PubMed ID: 23116337
[TBL] [Abstract][Full Text] [Related]
8. Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair.
Sharma A; Menon P; Muresanu DF; Ozkizilcik A; Tian ZR; Lafuente JV; Sharma HS
CNS Neurol Disord Drug Targets; 2016; 15(9):1092-1117. PubMed ID: 27538949
[TBL] [Abstract][Full Text] [Related]
9. Borneol, a messenger agent, improves central nervous system drug delivery through enhancing blood-brain barrier permeability: a preclinical systematic review and meta-analysis.
Zheng Q; Chen ZX; Xu MB; Zhou XL; Huang YY; Zheng GQ; Wang Y
Drug Deliv; 2018 Nov; 25(1):1617-1633. PubMed ID: 30334462
[TBL] [Abstract][Full Text] [Related]
10. Theoretical and practical applications of the intracerebroventricular route for CSF sampling and drug administration in CNS drug discovery research: a mini review.
Kuo A; Smith MT
J Neurosci Methods; 2014 Aug; 233():166-71. PubMed ID: 24937765
[TBL] [Abstract][Full Text] [Related]
11. From naturally-occurring neurotoxic agents to CNS shuttles for drug delivery.
Soddu E; Rassu G; Giunchedi P; Sarmento B; Gavini E
Eur J Pharm Sci; 2015 Jul; 74():63-76. PubMed ID: 25892455
[TBL] [Abstract][Full Text] [Related]
12. Intrathecal delivery of protein therapeutics to the brain: a critical reassessment.
Calias P; Banks WA; Begley D; Scarpa M; Dickson P
Pharmacol Ther; 2014 Nov; 144(2):114-22. PubMed ID: 24854599
[TBL] [Abstract][Full Text] [Related]
13. Impact of transporters and enzymes from blood-cerebrospinal fluid barrier and brain parenchyma on CNS drug uptake.
Wang Q; Zuo Z
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):961-972. PubMed ID: 30118608
[TBL] [Abstract][Full Text] [Related]
14. Targeting specific cells in the brain with nanomedicines for CNS therapies.
Zhang F; Lin YA; Kannan S; Kannan RM
J Control Release; 2016 Oct; 240():212-226. PubMed ID: 26686078
[TBL] [Abstract][Full Text] [Related]
15. Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood-Brain Barrier.
Stanimirovic DB; Sandhu JK; Costain WJ
BioDrugs; 2018 Dec; 32(6):547-559. PubMed ID: 30306341
[TBL] [Abstract][Full Text] [Related]
16. Applications of nanotechnology in drug delivery to the central nervous system.
Saeedi M; Eslamifar M; Khezri K; Dizaj SM
Biomed Pharmacother; 2019 Mar; 111():666-675. PubMed ID: 30611991
[TBL] [Abstract][Full Text] [Related]
17. The promise and perils of CNS drug delivery: a video debate.
Gendelman HE; Kabanov A; Linder J
J Neuroimmune Pharmacol; 2008 Jun; 3(2):58. PubMed ID: 18322803
[TBL] [Abstract][Full Text] [Related]
18. Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain.
Ruozi B; Belletti D; Pederzoli F; Forni F; Vandelli MA; Tosi G
CNS Neurol Disord Drug Targets; 2016; 15(9):1079-1091. PubMed ID: 27633786
[TBL] [Abstract][Full Text] [Related]
19. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations.
Thorne RG; Frey WH
Clin Pharmacokinet; 2001; 40(12):907-46. PubMed ID: 11735609
[TBL] [Abstract][Full Text] [Related]
20. On the future development of optimally-sized lipid-insoluble systemic therapies for CNS solid tumors and other neuropathologies.
Sarin H
Recent Pat CNS Drug Discov; 2010 Nov; 5(3):239-52. PubMed ID: 20722627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
